- Home
- NIE vs ERAS Comparison
NIE vs ERAS Comparison
Compare NIE & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIE
- ERAS
- Stock Information
- Founded
- NIE 2007
- ERAS 2018
- Country
- NIE United States
- ERAS United States
- Employees
- NIE N/A
- ERAS N/A
- Industry
- NIE Investment Managers
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- NIE Finance
- ERAS Health Care
- Exchange
- NIE Nasdaq
- ERAS Nasdaq
- Market Cap
- NIE 694.9M
- ERAS 723.8M
- IPO Year
- NIE N/A
- ERAS 2021
- Fundamental
- Price
- NIE $23.99
- ERAS $2.47
- Analyst Decision
- NIE
- ERAS Strong Buy
- Analyst Count
- NIE 0
- ERAS 5
- Target Price
- NIE N/A
- ERAS $5.90
- AVG Volume (30 Days)
- NIE 70.5K
- ERAS 1.2M
- Earning Date
- NIE 01-01-0001
- ERAS 11-12-2024
- Dividend Yield
- NIE 9.04%
- ERAS N/A
- EPS Growth
- NIE N/A
- ERAS N/A
- EPS
- NIE N/A
- ERAS N/A
- Revenue
- NIE N/A
- ERAS N/A
- Revenue This Year
- NIE N/A
- ERAS N/A
- Revenue Next Year
- NIE N/A
- ERAS N/A
- P/E Ratio
- NIE N/A
- ERAS N/A
- Revenue Growth
- NIE N/A
- ERAS N/A
- 52 Week Low
- NIE $18.61
- ERAS $1.64
- 52 Week High
- NIE $22.47
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- NIE 52.49
- ERAS 42.73
- Support Level
- NIE $24.32
- ERAS $2.51
- Resistance Level
- NIE $24.77
- ERAS $2.68
- Average True Range (ATR)
- NIE 0.34
- ERAS 0.21
- MACD
- NIE -0.09
- ERAS -0.04
- Stochastic Oscillator
- NIE 25.19
- ERAS 14.56
About NIE Virtus Equity & Convertible Income Fund of Beneficial Interest
Virtus AllianzGI Equity & Convertible Income Fund is a diversified, closed-end management investment company. Its investment objective is to seek total return comprised of capital appreciation, current income, and gains. The fund pursues its objective by investing in a diversified portfolio of equity securities and income-producing convertible securities. Its portfolio of investments comprises different sector investments such as aerospace and defense, banks, IT services, software, and others.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.